Author

Brian Erickson

Broad Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Neuroscience· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:proteomics· 2 Organism:human· 1

Frequent Co-Authors

Andrew G. ReidenbachiD· 2 shared Daniel A. SpragueiD· 2 shared Sonia M. VallabhiD· 2 shared Vanessa LaversenneiD· 2 shared Abdul Basit Shaikh· 1 shared Alyssa SeerleyiD· 1 shared Amy Q. WangiD· 1 shared Andrea Grindeland Panter· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersNeuroscience

Andrew G. ReidenbachORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Phenotypic screening for small molecules that lower PrP in cultured cells

Jeannine A. Frei, Andrew G. Reidenbach, Leo MH Xu, Raja Mohan Gopalakrishnan, Dominick Casalana, Daniel A. Sprague, Mark A. Bray, Amy Q. Wang, Vanessa Laversenne, Brian Erickson, Craig Braun, Samarjit Patnaik, Mckenzie Hall, Douglas S. Auld, Sonia M. Vallabh

The paper identifies two small molecules that lower PrP levels in cultured cells but show limited activity in human cell lines and in vivo.

Molecular and Cellular Neuroscience · Jul 9, 2026Peer-reviewedNeuroscience

PrP turnover in vivo and the time to effect of prion disease therapeutics

Taylor L Corridon, Jill O’Moore, Alyssa Seerley, Daniel A. Sprague, Yuan Lian, Vanessa Laversenne, Briana Noble, Nikita G Kamath, Fiona E. Serack, Abdul Basit Shaikh, Brian Erickson, Craig R. Braun, Kendrick DeSouza-Lenz, Michael Howard, Nathan Chan, , Eric Vallabh Minikel

The paper measures PrP half-life in vivo and shows it limits the time to effect of PrP-lowering therapies, with implications for drug development and clinical trial design.

PLoS Pathogens · May 26, 2026Peer-reviewedNeuroscience